Clinical Trial Update: Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching HIV-1 infected subjects from twice-daily HAART to a once-daily regimen to assess feasibility and outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 3 | Status: COMPLETED